Moderna, Pfizer Protocols May Make COVID Vaccines Hard to Compare

It will be difficult to compare Moderna, Inc. and Pfizer Inc.’s coronavirus vaccines based on their Phase 3 study designs, some vaccines experts said.

“Both trials appeared to be well designed,” based on publicly available information, said Ira Longini, co-director of the Center for Statistics and Quantitative Infectious Diseases Emerging Pathogens Institute at the University of Florida. But he added they suffer from the fact that they’re done independently.